2-Chlor-4-hydroxytriphenylmethan | 67723-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 2-Chlor-4-hydroxytriphenylmethan
• 英文别名: 2-chlorophenyl-4-hydroxyphenyl-phenyl-methane；2-Chlorophenyl-4-hydroxyphenylphenylmethane；4-[(2-chlorophenyl)-phenylmethyl]phenol
• CAS: 67723-79-9
• 化学式: C₁₉H₁₅ClO
• 分子量: 294.78
• InChiKey: QWIPNXUZCLOEBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  bromomagnesium phenolate 、 (2-氯苯基)-苯甲醇 以74%的产率得到
  参考文献：
  名称：

  CASIRAGHI G.; CASNATI G.; CORNIA M.; POCHINI A.; SARTORI G.; UNGARO R., J. CHEM. SOC. PERKIN TRANS., PART 1,1978, NO 4, 322-325

  摘要：

  DOI：

文献信息

• Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction
  申请人：——

  公开号：US20020119989A1

  公开（公告）日：2002-08-29

  The present invention relates to chemical compounds having inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca), and the use of such compounds for the treatment or alleviation of diseases or conditions relating to immune dysfunction. Moreover, the invention relates to a method of screening a chemical compound for inhibitory activity on an intermediate conductance Ca 2+ activated potassium channel (IK Ca).

  本发明涉及具有对中间电导性Ca2+激活钾通道（IK Ca）具有抑制活性的化合物，以及利用这种化合物治疗或缓解与免疫功能紊乱相关的疾病或症状。此外，本发明涉及一种筛选化合物对中间电导性Ca2+激活钾通道（IK Ca）具有抑制活性的方法。
• Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity
  申请人：——

  公开号：US20040248099A1

  公开（公告）日：2004-12-09

  The invention relates to the use of intermediate-conductance, calcium-activated potassium channels and/or the nucleic acids coding for the same, from humans or mice, for the diagnosis, prevention and/or treatment of illnesses associated with disturbed keratinocyte activity. The invention also relates to the use of the same for identifying pharmacologically active substances. The invention further relates to the use of modulators of intermediate-conductance, calcium-activated potassium channels for the diagnosis, prevention and/or treatment of illnesses associated with disturbed keratinocyte activity.

  本发明涉及使用来自人类或小鼠的中间导电、钙激活钾通道和/或编码其的核酸，用于诊断、预防和/或治疗与干扰角质形成细胞活动相关的疾病。本发明还涉及使用相同的物质来鉴定药理活性物质。本发明进一步涉及使用中间导电、钙激活钾通道的调节剂，用于诊断、预防和/或治疗与干扰角质形成细胞活动相关的疾病。
• Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
  申请人：——

  公开号：US20020119953A1

  公开（公告）日：2002-08-29

  The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

  本发明提供了一类化合物，可作为治疗镰状细胞病和以不需要的或异常的细胞增殖为特征的疾病，特别是与不需要的细胞增殖有关的炎症性疾病的有效药物。这些活性化合物是取代的三芳基甲烷化合物或其类似物，其中一个或多个芳基被杂芳基、环烷基或杂环烷基取代，和/或三级碳原子被不同的原子如 Si、Ge、N 或 P 取代。这些化合物可抑制哺乳动物细胞增殖，抑制红细胞的加多斯通道，减少镰状红细胞脱水和/或延缓红细胞镰状化或变形的发生。
• CASIRAGHI G.; CASNATI G.; CORNIA M.; POCHINI A.; SARTORI G.; UNGARO R., J. CHEM. SOC. PERKIN TRANS., PART 1,1978, NO 4, 322-325
  作者：CASIRAGHI G.、 CASNATI G.、 CORNIA M.、 POCHINI A.、 SARTORI G.、 UNGARO R.

  DOI：——

  日期：——
• CLOTRIMAZOLE METABOLITES IN THE TREATMENT OF SICKLE CELL DISEASE
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：EP0781128B1

  公开（公告）日：2005-11-23